Kevin Sayer

Kevin Sayer has served as Chairman, President, and CEO of Dexcom since 2015, leading the company that has fundamentally changed how people with diabetes manage their condition. Dexcom's continuous glucose monitoring (CGM) system consists of a small sensor inserted just under the skin that continuously measures interstitial glucose levels and wirelessly transmits readings to a smartphone app or receiver every five minutes — providing real-time blood sugar data, trend information, and customizable alerts for dangerous highs or lows. The Dexcom G7, the company's latest sensor, is roughly the size of a coin, lasts 10 days, requires no fingerstick calibration, and provides 60-second warm-up time. CGM has proven superior to traditional finger-prick blood glucose monitoring in clinical outcomes, reducing both HbA1c (the key measure of long-term blood sugar control) and time spent in dangerous hypoglycemia. Dexcom's historic market has been Type 1 diabetes (where patients produce no insulin and CGM is increasingly considered standard of care), but the far larger opportunity is Type 2 diabetes — a population of over 400 million globally, where CGM adoption is still in early stages. Dexcom's Stelo biosensor, a lower-cost, over-the-counter CGM for Type 2 and prediabetic users, represents this expansion. Key stock drivers include CGM adoption rates (particularly in Type 2 diabetes), sensor utilization and reorder rates, competitive dynamics against Abbott's FreeStyle Libre, insurance coverage expansion, international market penetration, and the impact of GLP-1 drugs on diabetes management paradigms.